Although the first-in-class…
Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall [...]
In its 2,000-patient Proteus…
In its 2,000-patient Proteus study, J&J tested Erleada’s benefits when [...]
After winning a broader FDA label…
After winning a broader FDA label in metastatic castration-resistant prostate [...]
In Lilly’s Libretto-432 ASCO…
In Lilly’s Libretto-432 ASCO readout, Retevmo showed an 83% reduction [...]
Seeking a share of the first-line…
Seeking a share of the first-line diffuse B-cell lymphoma market, [...]
Pharma companies need to…
Pharma companies need to strengthen and modernize patient support programs [...]
Philips has integrated animated…
Philips has integrated animated Disney characters and stories into MRI [...]
With a pediatric approval in hand…
With a pediatric approval in hand for Afrezza, MannKind may [...]
AstraZeneca has fired another shot…
AstraZeneca has fired another shot in its bladder cancer competition [...]
A group of over 20 global pharma…
A group of over 20 global pharma leaders met with [...]